Overexpression of HMGA2 in triple negative breast cancer and its correlation with lymph node metastasis
10.13315/j.cnki.cjcep.2015.05.018
- VernacularTitle:三阴型乳腺癌中 HMGA2高表达及其与乳腺癌转移的相关性
- Author:
Minghua LUO
;
Jian LI
;
Mumin SHAO
;
Guangyin YU
;
Weihua YIN
- Publication Type:Journal Article
- Keywords:
breast neoplasm;
molecular subtypes;
HMGA2;
immunohistochemistry
- From:
Chinese Journal of Clinical and Experimental Pathology
2015;(5):560-564
- CountryChina
- Language:Chinese
-
Abstract:
Purpose To detect high mobility group protein A2 (HMGA2) expression in breast cancer, and to analyze its relationship with clinicopathological features and the levels of HMGA2 in different molecular subtypes of breast carcinomas. Methods An immu-nohistochemical study was undertaken for measuring the levels of HMGA2 in 58 breast carcinomas. Results ( 1 ) The expression of HMGA2 was 0, 62. 5%, 60. 0%, 100. 0% and 80. 0% in Lum A, Lum B, HER-2-OE, basal-like breast carcinoma (BLBC) and un-classification phenotype respectively ( triple negative breast cancer, 92. 3%) . High expression of HMGA2 was associated with the tri-ple-negative breast cancer (TNBC) subtypes (P<0. 01). (2) An association was identified between high expression of HMGA2, and high tumor grade, lymph node metastasis (P<0. 05), positive Ki-67, CK5/6 and EGFR (P<0. 05), negative ER and PR (P<0. 01), but no association was observed for tumor size and patients’age. Conclusion An association is identified between high ex-pression, and high tumor grade, lymph node metastasis, positive Ki-67, EGFR and CK5/6, negative ER and PR, that means a high expression of HMGA2 is associated with an adverse outcome in breast cancer. High expression of HMGA2 are associated with the TNBC subtypes. Thus recognizing HMGA2 as a rational target in TNBC. The results of the study have implications for therapeutic target iden-tification and the design of future clinical trials for TNBC.
